Jun 2026 (Q2 FY26) — Aug 11, 2026
Harrow Q2 FY26 — Strong H2 Outlook Driven by Product Economics, Commercial Expansion, and Turviya Acquisition
Read the full callHarrow (HROW) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Harrow earnings: last reported Tue, 11 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 70.7 | +10.9% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -15.6 | −33.5 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -17.3 | −445.7% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$27.68 +1.47% · +$0.4
Performance −30.8% 1Y
1Y: $40.01 on 17 Oct 2025 → $27.68. High $54.8 (5 Jan 2026), low $27.24 (14 Oct 2026).
- Previous close
- $27.28
- 52-week range
- $27.24 – $54.8
- One year
- −34.30%
Overview
- Symbol
- HROW
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Harrow earnings calls (HROW)
Financials
What the filings say
Net profit, year on year: −446% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 49 | 67 | 48 | 64 | 72 | 89 | 44 | 71 |
| Operating profit | 1 | 13 | -11 | 11 | 15 | 16 | -22 | -11 |
| Operating margin | 2.7% | 19.3% | −23.5% | 17.9% | 20.6% | 17.5% | −50.0% | −15.6% |
| Other income | -6 | -7 | -7 | -6 | -14 | -5 | — | — |
| Interest | 6 | 6 | 7 | 6 | 6 | 5 | 5 | 6 |
| Profit before tax | -4 | 6 | -18 | 5 | 1 | 10 | -28 | -17 |
| Tax rate | −0.5% | −8.2% | — | 0.0% | — | — | −0.1% | 0.0% |
| Net profit | -4 | 7 | -18 | 5 | 1 | 7 | -28 | -17 |
| EPS ($ per share) | -0.12 | — | -0.50 | 0.14 | 0.03 | — | -0.74 | -0.46 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -74 | -74 | -77 | -95 | -109 | -134 | -151 | -157 |
| Total liabilities | 25 | 32 | 31 | 87 | 130 | 242 | 320 | 347 |
| Fixed assets | 6 | 5 | 4 | 3 | 3 | 4 | 4 | 3 |
| Investments | — | — | 28 | 9 | 6 | 9 | — | — |
| Total assets | 49 | 59 | 57 | 98 | 157 | 312 | 389 | 399 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 1 | 1 | -1 | 5 | 2 | 4 | -22 | 44 |
| Cash from investing | -2 | -2 | -1 | -19 | -2 | -153 | -33 | -5 |
| Cash from financing | 4 | -1 | 1 | 51 | 54 | 127 | 29 | -13 |
| Net cash flow | 3 | -2 | -1 | 38 | 54 | -22 | -27 | 26 |
| Capital expenditure | -2 | -1 | -1 | -2 | -3 | -1 | -2 | -1 |
| Free cash flow | -1 | -1 | -2 | 3 | -1 | 2 | -24 | 43 |
Insider filings
16 filings between Dec 12, 2025 and Aug 14, 2026.
Open market
decisions to buy or sellPurchases
$468.7K
4 purchases by 4 insiders
Sales
$9.63M
7 sales by 2 insiders
Compensation
not trading decisions- 3
- Option exercise — converted options into shares
- 2
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Opaleye Management Inc. | — | $9.18M | Mar 4, 2026 |
| Shojaei Amir | — | $450.0K | Aug 14, 2026 |
| BAUM MARK L | $302.0K | — | May 14, 2026 |
| BOLL ANDREW R. | $104.7K | — | May 14, 2026 |
| Graves Adrienne L | $31.1K | — | May 18, 2026 |
| SILVERNAIL LAUREN P | $31.0K | — | May 18, 2026 |
Latest filings (36)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 14, 2026 | Shojaei Amir CHIEF SCIENTIFIC OFFICER | Option exercise | 11,250 | $404.6K |
| Aug 14, 2026 | Shojaei Amir CHIEF SCIENTIFIC OFFICER | Sale | 11,250 | $450.0K |
| May 18, 2026 | SILVERNAIL LAUREN P Director | Purchase | 1,000 | $31.0K |
| May 18, 2026 | Graves Adrienne L Director | Purchase | 1,000 | $31.1K |
| May 14, 2026 | BOLL ANDREW R. PRESIDENT AND CFO | Purchase | 3,500 | $104.7K |
| May 14, 2026 | BAUM MARK L CHIEF EXECUTIVE OFFICER | Purchase | 10,000 | $302.0K |
| Mar 4, 2026 | Opaleye Management Inc. 10% owner | Sale | 4,263 | $169.1K |
| Mar 4, 2026 | Opaleye Management Inc. 10% owner | Sale | 134,000 | $5.32M |
| Mar 3, 2026 | Opaleye Management Inc. 10% owner | Sale | 59,000 | $2.31M |
| Mar 3, 2026 | Opaleye Management Inc. 10% owner | Sale | 1,309 | $51.3K |
| Feb 27, 2026 | Opaleye Management Inc. 10% owner | Sale | 5,000 | $270.9K |
| Jan 6, 2026 | Opaleye Management Inc. 10% owner | Sale | 20,000 | $1.07M |
| Dec 12, 2025 | BAUM MARK L CHIEF EXECUTIVE OFFICER | Option exercise | 180,000 | $711.0K |
| Dec 12, 2025 | BAUM MARK L CHIEF EXECUTIVE OFFICER | Tax withheld | 79,994 | $3.76M |
| Dec 12, 2025 | BOLL ANDREW R. PRESIDENT AND CFO | Option exercise | 60,000 | $237.0K |
| Dec 12, 2025 | BOLL ANDREW R. PRESIDENT AND CFO | Tax withheld | 26,665 | $1.25M |
| Jul 21, 2025 | BAUM MARK L CHIEF EXECUTIVE OFFICER | Option exercise | 600,000 | $4.72M |
| Jul 21, 2025 | BAUM MARK L CHIEF EXECUTIVE OFFICER | Tax withheld | 313,338 | $11.62M |
| Jun 10, 2025 | Opaleye Management Inc. 10% owner | Sale | 15,000 | $462.0K |
| Jun 9, 2025 | Opaleye Management Inc. 10% owner | Sale | 15,204 | $461.8K |
| Jun 4, 2025 | Opaleye Management Inc. 10% owner | Sale | 1,796 | $53.9K |
| Jun 3, 2025 | Opaleye Management Inc. 10% owner | Sale | 3,000 | $90.1K |
| May 13, 2025 | Opaleye Management Inc. 10% owner | Sale | 5,000 | $132.9K |
| May 12, 2025 | Opaleye Management Inc. 10% owner | Sale | 10,000 | $259.0K |
| Apr 7, 2025 | BAUM MARK L Chief Executive Officer | Tax withheld | 300,363 | $6.94M |
| Apr 7, 2025 | BOLL ANDREW R. Chief Financial Officer | Tax withheld | 136,745 | $3.16M |
| Apr 7, 2025 | SAHAREK JOHN P. CEO & President, ImprimisRx | Tax withheld | 109,475 | $2.53M |
| Apr 3, 2025 | SAHAREK JOHN P. CEO & President, ImprimisRx | Option exercise | 277,200 | $0 |
| Apr 3, 2025 | BAUM MARK L Chief Executive Officer | Option exercise | 762,300 | $0 |
| Apr 3, 2025 | BOLL ANDREW R. Chief Financial Officer | Option exercise | 346,500 | $0 |
| Mar 24, 2025 | Opaleye Management Inc. 10% owner | Sale | 5,000 | $150.1K |
| Mar 18, 2025 | Opaleye Management Inc. 10% owner | Sale | 5,000 | $148.2K |
| Feb 28, 2025 | Opaleye Management Inc. 10% owner | Sale | 5,000 | $140.3K |
| Jan 22, 2025 | Opaleye Management Inc. 10% owner | Sale | 20,000 | $711.8K |
| Sep 11, 2024 | SAHAREK JOHN P. CEO of ImprimisRx | Tax withheld | 45,140 | $1.87M |
| Sep 11, 2024 | SAHAREK JOHN P. CEO of ImprimisRx | Option exercise | 90,000 | $663.3K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for HARROW, INC.
Free account. Everything above stays public.
Write why you follow HARROW, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading